C4 Therapeutics
CCCC
CCCC
107 hedge funds and large institutions have $1.21B invested in C4 Therapeutics in 2021 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 43 increasing their positions, 14 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
107
Holders Change
+24
Holders Change %
+28.92%
% of All Funds
1.87%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.09%
New
36
Increased
43
Reduced
14
Closed
12
Calls
$1.92M
Puts
–
Net Calls
+$1.92M
Net Calls Change
+$1.92M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$134M |
| 2 |
BlackRock
New York
|
$99.6M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
$52.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
$53.2M |
| 5 |
LCM
Laurion Capital Management
New York
|
$30.9M |
Top Sellers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
$13.4M |
| 2 |
PA
Perceptive Advisors
New York
|
$85.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
$26.1M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
$42.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
$17.8M |
